HIGHLIGHTS
- who: Mohamad K. Elajami et al. from the Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, USA have published the paper: Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma, in the Journal: (JOURNAL)
SUMMARY
Lutetium 177 Lu-DOTATATE is a radiolabeled somatostatin analogue that binds to somatostatin receptors, mainly subtype 2 receptors. To treatment of neuroendocrine tumors, this drug is under clinical trials assessing its anti-tumor effects in meningioma (NCT03971461 and NCT04082520; ClinicalTrials.gov), glioblastoma (NCT05109728; ClinicalTrials.gov), neuroblastoma (NCT04903899, NCT03966651; ClinicalTrials.gov), pheochromocytoma and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.